Merrimack Pharmaceuticals, Inc.
MACK · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 13.95 | 5.49 | -0.36 |
| FCF Yield | -0.62% | -0.15% | -0.11% | -0.38% |
| EV / EBITDA | 31.60 | 711.02 | -321.08 | -291.19 |
| Quality | ||||
| ROIC | -16.36% | -2.75% | -2.82% | -2.98% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 3.01 | 1.23 | 0.73 | 1.71 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | – | – |
| Free Cash Flow Growth | -345.42% | -45.32% | 69.61% | -87.64% |
| Safety | ||||
| Net Debt / EBITDA | 350.01 | -22.86 | 11.46 | 17.80 |
| Interest Coverage | 0.00 | -2.78 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |